Medical devices, healthcare technology and the business of care
510(k) clearance · K254114

Baylis Connector Cable

Baylis Medical Technologies Inc · Decision date Jan 18, 2026

FDA DECISIONK254114

What did the FDA decide?

FDA records K254114 as a 510(k) premarket notification, with a decision dated Jan 18, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Jan 18, 2026

FDA source record

Regulatory record facts

Identifier
K254114
Regulatory pathway
510(k) premarket notification
Product code
DSA
Decision code
SESE
Decision date
Jan 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cable, Transducer And Electrode, Patient, (Including Connector).

Product code
DSA
FDA device class
2

FDA decision timeline

  1. K254114 received

    Application receipt date recorded by FDA.

  2. K254114 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DSA

Product / regulatory recordCompanyPathwayDecision dateSource
Cb Innovations, LLC510(k) clearanceOct 30, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Baylis Medical Technologies Inc

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Mississauga

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records